Encilor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Encilor

Understanding Encilor

Encilor is a pharmaceutical medication developed for the management of chronic conditions affecting the respiratory system. It belongs to a class of drugs known as leukotriene receptor antagonists. These medications work by interacting with specific chemicals in the body that contribute to inflammation and the narrowing of airways.

Mechanism of Action

The primary function of Encilor is to block the action of leukotrienes. Leukotrienes are inflammatory molecules that the body releases in response to various triggers, such as allergens or exercise. When these molecules bind to receptors in the lungs and nasal passages, they cause swelling, increased mucus production, and bronchoconstriction (tightening of the muscles around the airways).

By preventing leukotrienes from binding to their receptors, Encilor helps to:

  • Reduce swelling in the lining of the respiratory tract.
  • Minimize the production of excess mucus.
  • Keep the airways more open, facilitating easier breathing.

Clinical Applications

Encilor is primarily utilized as a long-term maintenance therapy. It is designed to be used consistently to help control symptoms and prevent respiratory distress from occurring. Its application is typically focused on two main areas:

  • Chronic Asthma Management: It is used as a daily treatment to help maintain clear airways and reduce the frequency of asthma episodes.
  • Allergic Rhinitis: It can assist in managing symptoms associated with seasonal or year-round allergies, such as nasal congestion, sneezing, and itching.

Unlike rescue inhalers, Encilor does not provide immediate relief during an acute respiratory attack. Instead, it serves as a preventative measure to stabilize the respiratory system over time.

Regulatory References

  1. Loratadine - StatPearls (NCBI Bookshelf)
  2. Antihistamines for allergies - MedlinePlus (NIH)

What side effects are possible with Encilor?

Possible Side Effects and Safety Information for Encilor (Loratadine)

This section outlines the officially documented adverse reactions and safety characteristics of Loratadine, based strictly on government regulatory documents.


Frequency-Classified Adverse Reactions

The safety profile is defined by frequency categories established in regulatory documents. Adverse reactions are grouped as follows:

  • Common (affecting 1 to 10 users in 100): Headache, Somnolence (drowsiness), Fatigue, Nervousness, Insomnia, and Increased appetite.

  • Very Rare (affecting less than 1 user in 10,000): These include Hypersensitivity reactions (e.g., angioedema and anaphylaxis), Convulsion, Tachycardia (rapid heartbeat), Palpitation, Abnormal hepatic function, and gastrointestinal effects like Nausea and Dry mouth.


System-Organ Class (SOC) Groupings

Official labeling organizes reported effects by the physiological system affected. Adverse reactions have been documented across the Nervous system (e.g., dizziness, somnolence), Gastrointestinal disorders (e.g., gastritis), Immune system (hypersensitivity), Cardiac (e.g., palpitation), and Skin and subcutaneous tissue disorders (e.g., rash, alopecia).


Population-Specific Safety Notes

The official labeling defines specific safety considerations for certain groups:

  • Severe Hepatic Impairment: Use requires particular caution due to the potential for reduced drug clearance.
  • Pregnancy and Lactation: As a precautionary measure, use during pregnancy is typically preferred to be avoided, and it is not recommended for women who are breast-feeding because the active substance is excreted in breast milk.

Safety-Related Restrictions

Encilor is formally contraindicated in individuals with documented hypersensitivity to Loratadine. Furthermore, the medicine should be discontinued approximately 48 hours prior to any scheduled skin allergy testing, as its antihistamine action can interfere with test results.

Overdose and Emergency Response

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Overdose is officially documented to present primarily with central nervous system and cardiovascular effects, including somnolence (drowsiness), tachycardia (fast heart rate), and headache. Overdosage may also increase the occurrence of anticholinergic symptoms.
Population-specific overdose notes Elderly patients and individuals with hepatic or renal impairment may be at increased risk of somnolence at higher than recommended doses.
Emergency-response statements In case of suspected overdose, immediate action is required: get medical help or contact a Poison Control Center right way. Treatment must be instituted and maintained immediately, and continuous medical monitoring is necessary following initial emergency management.

Overdose classifications (high-level)

Classification Official Regulatory Statement
Severity classification The potential severity is indicated by the documentation of cardiovascular effects and the mandatory instruction to seek emergency medical attention for a suspected overdosage.
Overdose-context constraints There is no specific antidote known for Loratadine overdose. Loratadine is also noted to be not removed by haemodialysis.

Resulting overdose structure

Official overdose statements:

  • Overdose management is symptomatic and supportive.
  • Procedures such as the administration of activated charcoal (as a slurry with water) or gastric lavage may be considered by medical professionals to manage the effects and facilitate removal of the unabsorbed active substance.
  • Urgent medical attention is required when overdosage is suspected, regardless of symptoms.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing the expected clinical symptoms, specifying that management must be symptomatic, and unequivocally mandating urgent help-seeking (contacting a Poison Control Center or emergency services) if an overdose is suspected. This framework strictly outlines the regulatory requirements for recognizing and responding to a potential overdosage event.

Therapeutic Uses of Encilor

What Encilor Treats: Main Uses and Benefits

Encilor (Loratadine) is applied across key therapeutic domains where additional symptomatic support is needed, generally used for managing the discomfort and functional interference caused by common allergic reactions. Its use is considered relevant in contexts involving heightened symptom expression that may disrupt daily stability. It is used to temporarily relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by allergies.


Managing Upper Respiratory and Nasal Allergy Symptoms

This domain is commonly used for the supportive management of Allergic Rhinitis, including both Seasonal Hay Fever and perennial forms of allergy. Encilor is relevant for managing symptom clusters such as frequent sneezing, a bothersome runny nose (rhinorrhea), and itching in the nose and throat. Applied in clinical settings marked by episodic or fluctuating symptom patterns, the key benefit is assisting with the management of these distressing nasal manifestations, which contributes to easing day-to-day discomfort.


Symptomatic Support for Hives and Allergic Skin Manifestations

Encilor is considered relevant in dermatological contexts characterized by histamine-driven reactions, such as Urticaria (hives) and generalized allergic rashes. It is used in situations involving recurrent or episodic manifestations of this condition. The primary application in this domain is to help ease the burden of symptoms like widespread itchy skin (pruritus) and the appearance of wheals, offering supportive relief that may help patients cope more steadily with difficult episodes.


Quick Fact: Relief for Ocular Symptoms Encilor is commonly used to help with the relief of eye symptoms, specifically watery, itchy, and red eyes, assisting with general comfort during allergic episodes.

The main indications where Encilor is commonly used to help include the symptomatic relief of Allergic Rhinitis (seasonal and perennial), Urticaria (hives), and other allergic skin manifestations involving itching.

Regulatory References

  1. Loratadine is used to temporarily relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by allergies

Eligibility and Restrictions for Use

The eligibility profile for Encilor is strictly defined by regulatory documents that classify who can and cannot use the medicine. Absolute non-eligibility, or contraindication, applies to patients with a known hypersensitivity to Loratadine or any component of the formulation. The medicine is also not established and often contraindicated for children younger than two years of age.

Age-related eligibility rules permit use in children mathbf2 years and older (usually liquid forms) and continue through adolescence and adulthood. Condition-specific eligibility rules require caution and a reduced initial dose for patients with severe hepatic impairment or severe renal impairment (GFR < 30 mL/min). This reflects a key eligibility-context constraint based on reduced drug clearance. Regarding pregnancy and lactation eligibility status, use is generally not recommended for women who are breastfeeding as the drug passes into human milk. For pregnancy, official guidance often states it is preferable to avoid use as a precautionary measure. Finally, certain formulations containing phenylalanine are restricted for use in patients with Phenylketonuria (PKU).

What should I know about interactions with other medicines?

The official regulatory information for Encilor details specific drug-drug interactions, primarily concerning medicines that affect certain liver enzymes. These interactions are based on the potential for pharmacokinetic changes resulting from the inhibition of hepatic cytochromes P450 3A4 and 2D6 by co-administered drugs.

Potential Drug-Drug Interactions

The most significant interacting medicinal product categories are those that act as inhibitors of CYP450 3A4 and 2D6. Specific interacting medicines listed in official documentation include Cimetidine, Erythromycin, and Ketoconazole.

  • Cimetidine is documented as inhibiting both CYP450 3A4 and 2D6 enzymes.
  • Erythromycin and Ketoconazole primarily inhibit CYP450 3A4.

Interaction Implications

These interactions may elevate the plasma concentrations of Encilor because the listed products inhibit the enzymes responsible for its metabolism. However, regulatory sources specifically note that while an increase in Encilor serum concentration occurs with these listed drugs, no adverse effects are reported from the clinical studies of co-administration.

In contrast to other agents in the same class, official labeling also includes a specific observation regarding food and substance interaction. Encilor has no potentiating effects when administered concurrently with alcohol, as demonstrated in formal psychomotor performance studies.

Mechanism of Action

How Encilor Works: Mechanism of Action

Encilor functions through a dual pharmacodynamic mechanism involving selective receptor antagonism and modulation of inflammatory signaling pathways. The drug and its active metabolite, Desloratadine, primarily act as inverse agonists at peripheral Histamine H1-receptors ( H1 R), stabilizing the receptor in an inactive conformation. This interaction decreases histamine-mediated signaling on target cells and modulates the initiation of the physiological response. The resultant physiological effect includes the limitation of vasodilation and reduced capillary permeability, which limits tissue extravasation and local fluid accumulation.

Beyond H1 R activity, the drug modulates the release of mediators from mast cells and influences the intracellular NF-kappa B inflammatory cascade. This pathway adjustment decreases the production of downstream pro-inflammatory cytokines, such as IL-6 and TNF-alpha, modulating immune signaling at the tissue level. Structurally, Encilor's low lipophilicity limits its transport across the blood-brain barrier (BBB), ensuring the effect is exerted peripherally, influencing local physiological responses rather than central ones.

Dosage and Administration Information

Official Administration Guidelines for Encilor (Loratadine)

Encilor is used solely via the oral route of administration. It is available in multiple forms, including standard tablets, oral solutions, and specific preparations like chewable or orally disintegrating tablets.

The standard regimen for adults and children greater than or equal to 6 years and greater than or equal to 30 kg is 10 mg administered once daily. Guidelines specify that this dose must not be exceeded in a 24-hour period. The medicine’s administration is independent of food intake; it may be taken without regard to mealtime. For specific solid forms, handling instructions specify that orally disintegrating tablets are designed to dissolve on the tongue, and chewable tablets must be masticated before swallowing.

Usage modifications are prescribed based on an individual's organ function. For patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than or equal to 30 mL/min), the standardized dose is reduced to 10 mg every other day. Furthermore, a key administration constraint specifies that Encilor must be discontinued for at least 48 hours prior to performing any diagnostic skin-prick testing, as the presence of the medication can interfere with the results. If a dose is missed, individuals should resume the regular once-daily schedule, either by taking the forgotten dose immediately or skipping it if the next dose time is imminent.

Recent Clinical Evidence

Encilor: Recent Clinical Evidence

The research base for Encilor (loratadine) includes controlled trials and systematic reviews. These studies were conducted to examine symptom measurements in groups receiving the compound for common allergic conditions. Findings describe group patterns and contribute to the overall understanding of symptom patterns, but research does not determine whether an individual will respond similarly.


Evidence for Use in Allergic Rhinitis (Hay Fever)

Research into allergic rhinitis, a condition characterized by fluctuating or episodic manifestations, primarily includes short-term controlled trials. Researchers examined patient-reported outcomes describing perceived discomfort, focusing on the Total Nasal Symptom Score (which tracks sneezing, running nose, and itching) and the Total Ocular Symptom Score (which tracks itchy, watery, and red eyes).

Findings describe patterns related to the measurement of symptoms in groups receiving the compound compared to placebo groups across short-term observation periods. Comparative studies have explored measurements related to nasal congestion, but reported measurements varied in these reports. Studies focusing on this specific symptom axis show less consistent patterns than those examining sneezing or itching.


Evidence for Use in Chronic Urticaria (Hives)

Research has evaluated the compound in contexts involving chronic urticaria, a condition marked by functional limitations and periods of heightened symptom activity. Studies explored outcomes related to physical discomfort by tracking the severity and frequency of pruritus (itching) and monitoring the count or size of wheals (hives). Findings describe patterns related to the measurement of skin manifestations in actively studied groups compared to the placebo groups in short-term research.


What Remains Uncertain About Encilor's Research

The research landscape highlights several areas where data remain insufficient or uncertain. For example, evidence is limited for long-term functional outcomes and the durability of response over many years, as most available research covers only acute or short-term periods. Additionally, data for certain groups remain insufficient, particularly for children under 2 years old with allergic rhinitis and those under 6 years old with chronic urticaria.

Key Studies & References

  1. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis (Symptom score reduction data)

Frequently Asked Questions (FAQ)

Common questions about Encilor (FAQ)


Q: How quickly should I expect to feel the effects of Encilor?

A: Studies and official information indicate that the relief of allergic symptoms may begin relatively quickly after taking the medicine. Clinical research has shown that symptom relief can start as early as 75 minutes in groups of adults with allergic rhinitis.


Q: Are there any specific foods or drinks to avoid while on Encilor?

A: Regulatory information indicates that Encilor can be taken without regard to mealtime. Furthermore, formal studies have demonstrated that the medicine has no potentiating effects when taken concurrently with alcohol.


Q: Is Encilor safe for people with liver problems?

A: Official product information advises that the medicine should be administered with caution in patients who have severe liver impairment, as a reduced dose is typically recommended to manage drug clearance. Concerns about liver impairment should be discussed with a healthcare professional.


Q: Can Encilor be taken with vitamin supplements?

A: While there is limited specific information available in the official labeling regarding vitamins or common supplements, they are not typically listed as being major interacting agents. Questions about taking the medicine with any vitamin or supplement are best directed to a healthcare provider or pharmacist.


Q: Will Encilor affect my ability to drive or operate machinery?

A: Encilor is classified as a non-drowsy antihistamine, but regulatory warnings indicate that drowsiness is a possible side effect for some people. Individuals should be aware of how the medicine affects them before driving or operating machinery.


Q: Does Encilor cause weight gain or weight loss?

A: Official documents list increased appetite as a common side effect of the medicine. In post-marketing surveillance, weight gain has also been reported, though the frequency is not precisely determined. Weight loss is not typically listed as a reported effect.


Q: Can Encilor be taken on an empty stomach?

A: Yes, according to the official administration guidelines, Encilor may be taken without regard to mealtime. This means the medicine can be taken with or without food.


Q: How long before surgery should Encilor be stopped?

A: The official product information specifically states that Encilor must be stopped for at least 48 hours before any diagnostic skin-prick allergy testing to avoid interfering with test results. Specific instructions regarding general surgery should be requested from a prescribing clinician or surgical team.


Q: Does Encilor interact with herbal remedies like St. John's Wort?

A: Regulatory-backed medical guidance sometimes advises caution with herbal remedies that affect liver enzymes. For instance, St. John’s Wort may potentially reduce the medicine's effectiveness. Consultation with a healthcare provider or pharmacist is recommended before combining Encilor with any herbal remedy.


Q: Are there any known long-term side effects associated with Encilor?

A: Most clinical data regarding Encilor comes from short-term trials. While regulatory documents list acute and common adverse effects, they also note that evidence regarding long-term functional outcomes is limited.


Q: Does Encilor affect blood pressure?

A: While this medicine is not typically identified as a concern for blood pressure, hypertension (high blood pressure) has been reported as an adverse event in post-marketing data. However, the frequency of this occurrence is not known.


Q: Are there any mental health side effects linked to Encilor?

A: Official safety data lists nervousness and insomnia (difficulty sleeping) as common adverse effects related to the nervous system. Less frequently, severe effects like convulsion have been reported.


Q: Does Encilor change the way other medications are absorbed?

A: Official information indicates that Encilor can interact with medicines that affect certain liver enzymes, such as cytochrome P450, which are responsible for metabolism. It can also affect the body's drug transport systems, which may change the level or effect of co-administered drugs.


Q: Why does Encilor need to be taken consistently at the same time?

A: Encilor is a once-daily medicine. Taking it at the same time each day helps to maintain a steady and consistent level of the active drug in the body. This steady level is important for providing continuous and effective symptom relief over 24 hours.


Q: Do people with asthma need to be careful when taking Encilor?

A: Encilor is an antihistamine used to relieve allergy symptoms. The official label does not contain a specific contraindication (a reason to absolutely avoid it) related to asthma. However, concerns regarding Encilor use with asthma should be addressed with a healthcare provider.


Q: What are the chances of experiencing a rare but severe side effect from Encilor?

A: Severe side effects, such as a serious hypersensitivity reaction or convulsion, are categorized in official documents as Very Rare. This means they are estimated to affect less than 1 user in 10,000.


Q: Can Encilor cause changes in vision?

A: Changes in vision have been reported as adverse events in post-marketing surveillance, though the exact frequency is unknown. Specifically, events such as blurred vision have been reported.

How should Encilor be stored and disposed of?

How to Store and Dispose of Encilor (Loratadine)

Official regulatory labeling dictates specific storage and disposal requirements for Encilor to maintain stability and ensure safety.

Storage Conditions

Encilor must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should be kept in its original container, tightly closed. Liquid forms must be protected from freezing. A primary requirement for all formulations is that they must be stored out of the sight and reach of children.

️ Disposal Requirements

To dispose of unused or expired Encilor, it should not be flushed down the toilet or sink. If a drug take-back program is unavailable, mix the medication with an undesirable substance (such as coffee grounds or dirt), seal it in a container, and dispose of it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Encilor found in:

A-Z Index: